Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of Non-Hodgkin’s Lymphoma and in 2020, there were approximately 4,600 people in Canada diagnosed with Non-Hodgkin’s Lymphoma.
(Cancer Care Society, 2020; Goldkuhle et al., 2019; Lymphoma Canada, 2020; Morrison et al., 2015)
DLBCL accounted for 30 to 40% of all NHL cases.
(Cancer Care Society, 2020; Goldkuhle et al., 2019; Lymphoma Canada, 2020; Morrison et al., 2015)
DLBCL is prevalent in patients above the age of 60, median age being 65.
(Cancer Care Society, 2020; Goldkuhle et al., 2019; Lymphoma Canada, 2020; Morrison et al., 2015)
Some experts believe this disease affects both genders equally while others states that men are more affected than women.
(Cancer Care Society, 2020; Goldkuhle et al., 2019; Lymphoma Canada, 2020; Morrison et al., 2015)
This disease starts primarily with swelling in the lymph nodes and spleen and progresses with anemia, thrombocytopenia, and leukocytopenia.
(Cancer Care Society, 2020; Goldkuhle et al., 2019; Lymphoma Canada, 2020; Morrison et al., 2015)
Survival rates for 63% of the affected individuals are an estimated 5 years but majority will be approximately three years with 30 to 40% relapse rate; depending on prognostic factors, comorbidities, and time from initial treatment
(Cancer Care Society, 2020; Goldkuhle et al., 2019; Lymphoma Canada, 2020; Morrison et al., 2015)
Treatment regiments:
- Chemotherapy
- Autologous stem cell transplant (own cells)
- Allogeneic stem cell transplant (donor)
- Car-T therapy
(Cancer Care Society, 2020; Goldkuhle et al., 2019; Lymphoma Canada, 2020; Morrison et al., 2015)